Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma

INTRODUCTION: Poly-(ADP)-ribose polymerase (PARP) inhibitors are successfully used for treatment of BRCA-mutated (mut) breast cancers and are under extensive evaluation for BRCA- and PALB2-mutated pancreatic ductal adenocarcinoma (PDAC). However, the optimal treatment regimen for BRCA/PALB2-mutated...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:ESMO Open
Egile Nagusiak: Seeber, Andreas, Zimmer, Kai, Kocher, Florian, Puccini, Alberto, Xiu, Joanne, Nabhan, Chadi, Elliott, Andrew, Goldberg, Richard M, Grothey, Axel, Shields, Anthony F, Battaglin, Francesca, El-Deiry, Wafik S, Philip, Philip A, Marshall, John L, Hall, Michael, Korn, W Michael, Lenz, Heinz-Josef, Wolf, Dominik, Feistritzer, Clemens, Spizzo, Gilbert
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2020
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7684832/
https://ncbi.nlm.nih.gov/pubmed/33229504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2020-000942
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak